Full Text | PDF

Theranostics 2011; 1:201-210. doi:10.7150/thno/v01p0201 This volume Cite

Review

Integrin Targeted Delivery of Radiotherapeutics

Zhaofei Liu^1,2✉, Fan Wang^1,2, Xiaoyuan Chen^{3 ✉}

1. Medical Isotopes Research Center, Peking University, Beijing, China
2. Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing, China
3. National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Health (NIH), Bethesda, MD

✉ Corresponding author: Dr. Xiaoyuan Chen, Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Health (NIH), 31 Center Dr, 31/1C22, Bethesda, MD 20892, USA; Tel: 301-451-4246; Email: shawn.chengov; Dr. Zhaofei Liu, Medical Isotopes Research Center, Peking University, 38 Xueyuan Road, Beijing 100191, China; Tel: 86-10-82802871; Email: liuzfedu.cn More

Abstract

Targeted radionuclide therapy, which is based on the selective delivery of a sufficient radiation dose to tumors without significantly affecting normal tissues, is a promising therapeutic approach for the treatment of a wide variety of malignancies. Integrins, a family of cell adhesion molecules, play key roles during tumor angiogenesis and metastasis. Among all the integrins, αvβ3 seems to be the most important in the process of tumor angiogenesis. Integrin αvβ3 is highly expressed on activated endothelial cells, new-born vessels as well as some tumor cells, but is not present in resting endothelial cells and most normal organ systems, making it a suitable target for anti-tumor therapy. In this review, we summarize the current development and applications of antibody-, peptide-, and other ligand-based integrin targeted radiotherapeutics for tumor radiation therapy.

Keywords: Cancer, integrin, radionuclide, radioimmunotherapy (RIT), peptide receptor radionuclide therapy (PRRT)

Citation styles

©2024 Ivyspring International Publisher. Terms of use